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a  b  s  t  r  a  c  t
Hookworm  infection  is one  of  the  world’s  most  common  neglected  tropical  diseases  and  a  leading  cause
of  iron  deficiency  anemia  in low-  and  middle-income  countries.  A Human  Hookworm  Vaccine  is  cur-
rently  being  developed  by  the Sabin  Vaccine  Institute  and  is  in phase  1  clinical  testing.  The  candidate
vaccine  is  comprised  of  two  recombinant  antigens  known  as  Na-GST-1  and  Na-APR-1,  each  of which  is
an important  parasite  enzyme  required  for  hookworms  to successfully  utilize  host  blood  as a  source  of
energy.  The  recombinant  proteins  are  formulated  on  Alhydrogel® and  are  being  tested  in  combination
with  a synthetic  Toll-like  receptor  4 agonist.  The  aim  of the  vaccine  is  to induce  anti-enzyme  antibodies
that  will  reduce  both  host  blood  loss  and  the  number  of  hookworms  attached  to  the  gut. Transfer  ofa-GST-1
a-APR-1
nemia
the  manufacturing  technology  to the  Oswaldo  Cruz  Foundation  (FIOCRUZ)/Bio-Manguinhos  (a Brazilian
public  sector  developing  country  vaccine  manufacturer)  is planned,  with  a  clinical  development  plan  that
could lead  to registration  of  the vaccine  in Brazil.  The  vaccine  would  also  need  to be introduced  in  the
poorest  regions  of  Africa  and  Asia,  where  hookworm  infection  is highly  endemic.  Ultimately,  the vaccine
could  become  an  essential  tool  for achieving  hookworm  control  and  elimination,  a key  target  in the  2012
London  Declaration  on  Neglected  Tropical  Diseases.
© 2012 Elsevier Ltd. All rights reserved.
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. Background
Hookworm infection is a leading cause of iron-deficiency
nemia in rural areas of the world’s poorest countries [1].  An esti-
ated 700 million people chronically harbor hookworms in their
ntestines—most of these people survive on less than $1–2 per day,
 benchmark threshold for defining global poverty [1,2]. Indeed,
ookworm infection is considered to be among the two  most
ommon chronic infections of the “bottom billion” and based on
isability-adjusted life years (DALYs) lost, it is the most important
eglected tropical disease (NTD) and the second most important
arasitic infection (after malaria) [2,3].
Hookworms can live for years in the human intestine where they
eed on host blood. Most of the morbidity is due to chronic blood
oss that results in iron-deficiency anemia and hypoalbuminemia
1]. Recent evidence points to hookworm infection emerging as
n important global threat to maternal–child health. Both chil-
ren and pregnant women are especially vulnerable because of
heir higher iron demands and lower baseline iron reserves [4,5].
hildren with moderate and heavy hookworm infections develop
rowth stunting and intellectual, cognitive, and educational deficits
4]. As they become adults entering the workforce, individuals with
hronic hookworm infection experience substantial reductions in
age-earning potential [6].  Moreover between one-quarter and
ne-third of pregnant women  in Africa are infected with hook-
orms, which can result in severe anemia, increased maternal
orbidity and mortality, and fetal loss or prematurity [5].  Thus,
ookworm infection is a major impediment to achieving Millen-
ium Development Goals (MDGs) and targets for ameliorating
overty and improving maternal and child health [4].
Adding to the disease burden resulting from hookworm
nfection is the observation made in sub-Saharan Africa
hat there is extensive geographic overlap with malaria, and
ookworm–malaria co-infections are widespread [7].  The effect
f concurrent hookworm and malaria infections on the severity of
nemia has been shown to be additive or synergistic, and malaria
nfections on the incidence of anemia have been shown to be
ynergistic and increase the risk of severe and profound anemia
8].
A Human Hookworm Vaccine is being developed by the prod-
ct development partnership (PDP) of the Sabin Vaccine Institute
9,10]. The vaccine is being designed to target Necator amer-
canus, the hookworm species responsible for approximately
hree-quarters or more of all human hookworm infections [11].
he eventual goal is to license a vaccine that contains two recom-
inant hookworm antigens, Na-GST-1 and Na-APR-1, which are
ormulated on an aluminum hydroxide adjuvant (Alhydrogel®).
linical testing will evaluate whether an additional adjuvant, an
queous formulation of a synthetic Toll-like receptor 4 (TLR 4) ago-
ist (glucopyranosyl lipid A [GLA-AF]), will be required to achieve
cceptable immunogenicity [9].
Na-GST-1 is a 24 kDa recombinant N. americanus glutathione-
-transferase expressed in yeast (Pichia pastoris) [12,13],  while
a-APR-1 is a 45 kDa recombinant N. americanus aspartic pro-
ease expressed in tobacco plants. For safety and stability reasons,
a-APR-1 was modified through site-directed mutagenesis to
roduce a recombinant protein devoid of proteolytic activity
14,15]. Preclinical proof-of-concept that both recombinant Na-
ST-1 and Na-APR-1 can induce protective efficacy has been
emonstrated though challenge studies conducted in laboratory
nimals (reviewed in [9]).Na-GST-1 has been manufactured at pilot scale according to cur-
rent Good Manufacturing Practices (cGMP). Following regulatory
submissions in the United States and Brazil, Na-GST-1 is currentlyS (2013) B227– B232
in phase 1 clinical trials in healthy adult volunteers in the United
States and Brazil.
• Na-APR-1 has also undergone cGMP manufacture at pilot scale.
An investigational new drug (IND) filing for this antigen formu-
lated on Alhydrogel® will be submitted to the United States Food
and Drug Administration and the Brazilian regulatory agency (the
Agencia Nacional de Vigilância em Saúde) in late 2012 or 2013.
Following phase 1 testing of each hookworm vaccine candidate
antigen in adults and children, they will be combined into a sin-
gle product, assuming that both have been shown to be safe and
immunogenic. This co-formulated product will be tested in phase
2b and 3 studies in hookworm-endemic regions of Brazil and likely
sub-Saharan Africa to evaluate its efficacy in preventing moderate
and heavy infections and the resulting intestinal blood loss and ane-
mia. In addition, early in clinical development a proof-of-concept
challenge trial is being considered in hookworm-naïve adult vol-
unteers who  are vaccinated and then challenged with infective
N. americanus larvae. Previous studies of experimental hookworm
infection have demonstrated that it is feasible, safe, and reasonably
well tolerated (depending on the dose of infectious larvae) [16–18].
This vaccination-challenge trial would be conducted after the ini-
tial phase 1 trials of each recombinant antigen in adults to provide
an early indication of their potential efficacy.
The target product profile of the Human Hookworm Vaccine
includes the following important features [9]:
1. The vaccine is intended for children under the age of 10 years
who  are at risk for acquiring moderate and heavy hookworm
infections in endemic areas of developing countries.
2. The vaccine will be administered by intramuscular injection up
to two doses and will require storage between 2 ◦C and 8 ◦C.
3. The vaccine can be administered concurrently with other child-
hood vaccines such as the measles vaccine.
4. Vaccine efficacy of at least 80% in preventing moderate and heavy
hookworm infections caused by N. americanus.
Widespread use of an effective Human Hookworm Vaccine
would significantly improve global public health and as outlined
below could also become a critical technology for the eventual
elimination of hookworm infection in low- and middle-income
countries. Such a vaccine has been described as an ‘antipoverty vac-
cine’ because of its potential to improve the economic development
of affected populations in addition to its positive impact on health
[10]. In addition, due to the synergistic effect of concurrent infec-
tion with malaria and hookworm on incidence of anemia, using
the vaccine in sub-Saharan Africa could potentially also reduce the
burden of disease due to Plasmodium falciparum.
2. Main barriers and challenges
Licensure and global access to the Human Hookworm Vaccine
will face significant scientific, programmatic, and commercial chal-
lenges, as described below.
2.1. Scientific challenges
Currently there are no licensed anthelminthic vaccines for
humans. Two experimental schistosomiasis vaccines are under-
going early stage clinical testing in Brazil and sub-Saharan Africa
[19,20], while the Human Hookworm Vaccine is the only vac-
cine in clinical development for hookworm infection. Hookworms
are complex multicellular parasites, so that producing an effi-
cacious vaccine against this helminth is in some respects an
even more formidable challenge than producing vaccines against
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nicellular parasites such as those that cause malaria and other pro-
ozoan infections. The feasibility of producing an efficacious vaccine
gainst hookworm has been reviewed previously and is based on
ast successes in developing an effective irradiated larval canine
ookworm vaccine and in demonstrating the efficacy of recombi-
ant protein vaccines in laboratory animal-challenge studies [9,21].
The major scientific hurdles in developing a hookworm vaccine
or humans can be summarized as follows, and have been reviewed
reviously in Refs. [9,21]:
. Achieving the target product profile for the Human Hookworm
Vaccine will require that the vaccine induces high levels of
antigen-specific antibodies. These antibodies will target two
key parasite enzymes involved in both hemoglobin digestion
and maturation of hookworm larvae into adult worms that are
attached to the host intestine. Na-GST-1 is a heme-binding pro-
tein that is thought to be involved in detoxification of free heme
by the parasite, whereas Na-APR-1 is a hemoglobinase required
for hemoglobin digestion (reviewed in [9]). In laboratory ani-
mals, antibodies induced against these two enzymes result in
diminished host intestinal blood loss and prevention of anemia
following challenge infection (reviewed in [9]). However, the
level of anti-enzyme antibodies required to achieve sufficient
neutralization that will prevent establishment of infection has
not yet been determined (i.e., an antibody-based correlate of pro-
tection has not been derived). Additionally, it is not yet known
whether Alhydrogel® and GLA-AF will be adequate as adjuvants
for promoting the production of the desired amounts of anti-
enzyme antibodies.
. N. americanus induces robust but mostly ineffective immune
responses in the human host. Moreover, N. americanus
hookworms have evolved to strongly immunomodulate and
down-regulate the host immune response to enable parasite sur-
vival in the host for months or even years [22]. In the absence of
protective immunity during natural infection, we have few clear
leads to best direct the human immune system to reduce the
number of hookworms in the gut and thereby reduce host blood
loss.
. To compound the problem outlined above, hookworm infec-
tion steers the immune response to parasites antigens (and
possibly bystander antigens) toward strong Th2 responses, asso-
ciated with increased levels of total and specific IgE antibodies
[22–25]. This tendency to induce IgE to hookworm antigens
has been shown to be especially true for those expressed by
infective larvae after they penetrate the host skin, such as Na-
ASP-2 [23]. Such antigens have been found to be unsuitable
for clinical development, since when used as vaccine com-
ponents they can induce immediate-type allergic reactions in
previously exposed individuals [23]. As a result of this safety con-
cern with larval antigens, PDP efforts are instead now focused
on developing adult hookworm antigens, as described above
[9].
. Neither recombinant hookworm antigen induces sterilizing
immunity in laboratory animals, nor is it expected that a hook-
worm vaccine will induce sterilizing immunity in humans.
Instead it is anticipated that the Human Hookworm Vaccine
will result in substantial reductions both in the number of
hookworms and in the amount of hookworm-induced intestinal
blood loss. Thus, the vaccine will prevent anemia and disease-
producing moderate and heavy hookworm infections, but not
necessarily subclinical light hookworm infections (as deter-
mined on the basis of quantitative fecal egg counts).. The minimally acceptable duration of protection for the Human
Hookworm Vaccine has not been established. A recent analysis
indicates that the vaccine must sustain protective immunity for
at least 5 years to be cost-effective (see below).S (2013) B227– B232 B229
2.2. Programmatic challenges
A key programmatic challenge to operationalizing an eventual
licensed Human Hookworm Vaccine is to successfully incorpo-
rate it into existing control programs. Currently there are two
products already in use, namely two  anthelminthic drugs of
the benzimidazole class (i.e., albendazole and mebendazole). In
hookworm-endemic regions, each drug is currently being deployed
in programs of regular ‘deworming’ or mass drug administration
(MDA) in order to reduce the burden of hookworm and other soil-
transmitted helminth infections such as ascariasis and trichuriasis.
A 2001 World Health Assembly resolution called for the expan-
sion of these deworming programs in order to reach annually (or
twice or three-times annually in areas of high transmission) most
or all of the world’s school-aged children at risk for acquiring soil-
transmitted helminth infections [26]. Today, these two  drugs are
largely being donated by GlaxoSmithKline and Johnson & Johnson
for albendazole and mebendazole, respectively [26].
In sub-Saharan Africa and elsewhere in developing countries,
hookworm infection is co-endemic not only with other soil-
transmitted helminth infections, but also with several other NTDs,
including schistosomiasis, lymphatic filariasis, onchocerciasis, and
trachoma [4,27].  The January 2012 London Declaration on the
NTDs emphasized the importance of targeting hookworm through
increased control efforts, integrated with the control or elimi-
nation of several other NTDs [28]. The major emphasis of such
efforts is based on MDA  using a so-called “rapid impact package”
of medicines donated by the pharmaceutical companies, which
includes either albendazole or mebendazole, but also ivermectin,
praziquantel, and azithromycin [4,26,27].
Whereas MDA  for NTDs such as lymphatic filariasis, onchocer-
ciasis, and trachoma has been shown to result in the elimination
of these diseases in more than two dozen countries, to date it
has not resulted in the elimination of hookworm or the other
soil-transmitted helminths [29]. The reasons for this failure are
several:
1. According to a recent systematic review, mebendazole cures on
average only 15% of hookworm infections, although reported egg
count reduction rates (a surrogate measure of reduction in worm
burden) are quite variable, ranging from 0% to as high as 68% for
N. americanus infection, and 98% reduction for mixed N. amer-
icanus and Ancylostoma duodenale hookworm infections [30].
Similarly, mebendazole has not been shown to improve anemia
prevalence when used as part of MDA  [5].  The reasons for such
drug failures are unclear, but the observation that repeated use
of mebendazole in the same geographic area is associated with
diminishing efficacy [31] has led some investigators to suggest
the possibility of emerging drug resistance, although whether
resistance has actually occurred is considered controversial and
is as yet unproven [9].
2. Albendazole currently has a higher reported rate of cure for
hookworm [30], but drug failure has also been reported [32] and
in some areas of Africa post-treatment reinfection can occur in
less than a year [33]. Rapid post-treatment reinfection in areas
of high transmission should prompt twice or thrice annual treat-
ment as recommended by the WHO  [34]. However, such frequent
deworming is often considered impractical or not feasible for
logistical and cost reasons.
3. Deworming is carried out primarily in school-aged or preschool
children. Whereas for ascariasis and trichuriasis the highest
intensity (worm burden) infections occur in children, for hook-
worm infection it is typically the adults (including pregnant
women) who  have the highest worm burdens [35]. Therefore,
whereas frequent and periodic deworming has been shown
to interrupt transmission of Ascaris lumbricoides in endemic
B230 P.J. Hotez et al. / Vaccine 31S (2013) B227– B232
Fig. 1. Benefit of adding an effective Human Hookworm Vaccine to Mass Drug
Administration (MDA) in order to achieve hookworm elimination, using an eco-
nomic dynamic transmission compartment model with compartments representing
human and free-living hookworm populations. In this scenario, albendazole is
administered annually to 75% of children ages 1–14 and the MDA  + vaccination
(2  doses) is administered to the same group once every 5 years (assuming a
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Fig. 2. Benefit of an effective Human Hookworm Vaccine in reducing disease bur-
den, as measured by disability adjusted life years (DALYs), relative to MDA  alone.-year duration of vaccine protection). Albendazole cure rate = 78.4%; vaccine effi-
acy = 70%; mean baseline worm burden = 30 (adults), 15 (children). Top: MDA  alone.
ottom: MDA  + vaccination.
communities [36], hookworm transmission would be expected
to continue unabated if only children are targeted with MDA.
Such observations point to the need for universal coverage, i.e.,
deworming of children and adults, if hookworm elimination
was to be targeted through use of MDA  alone.
Global concerns about the effectiveness and/or sustainability
f MDA  for control of hookworm have prompted international
fforts to develop and test technologies, which could comple-
ent deworming and possibly lead to the eventual elimination
f hookworm infection as a cost-effective public health control
easure.
An independent modeling exercise has concluded that com-
ared with regular MDA, an effective hookworm vaccine would be
ost-effective (in many cases, highly cost-effective or even cost-
aving, that is ‘economically dominant’) across a large number
f scenarios of vaccine cost and prevalence of infection [37 and
npublished results]. In this analysis, when combined with MDA
 hookworm vaccine led to cost savings and improved health
ompared to MDA  alone for both school-aged children and non-
regnant women of reproductive age as long as the vaccine was at
east 30% effective in preventing infection, 40% effective in reduc-
ng egg production, and cost less than $100 per fully vaccinated
ndividual [37]. Additional analyses have indicated that a vac-
ine that induces protection of at least 5 years’ duration could
ead to the interruption of hookworm transmission and reduce
he burden of disease among both children and adults [unpub-
ished results] (Fig. 1), which is a necessary requirement for theOnly  disability resulting from anemia is included in this analysis. Albendazole cure
rate  = 78.4%; vaccine efficacy = 70%; mean baseline worm burden = 30 (adults), 15
(children).
elimination of hookworm in endemic areas [29]. These scenarios
include the possibility of vaccinating children following adminis-
tration of an anthelminthic (‘vaccine-linked chemotherapy’), which
would result in a significantly enhanced and more rapid reduction
in disease burden (as measured by DALYs) relative to MDA  alone
[unpublished results] (Fig. 2).
Since it is impossible to predict if pre-vaccination admin-
istration of an anthelminthic or continued exposure following
vaccination will have an effect (either positive or negative) on
vaccine-induced immunity, the effect of these two potential mod-
ifiers was assumed to be neutral in the modeling exercises
mentioned above. Questions such as these will be investigated dur-
ing clinical trials of the vaccine. In addition, since the number of
vaccine doses that will be needed to induce protective immunity in
a vaccinated individual is currently unknown, it has been assumed
to be two for the purposes of planning and modeling.
Despite the assumed economic dominance of the Human
Hookworm Vaccine, its comparative cost effectiveness relative to
deworming, and the vaccine’s potential for interrupting trans-
mission and effecting elimination, the idea of a vaccine-centered
approach to hookworm control has not been widely discussed or
debated by the global public health community. There are several
possible reasons for this, including:
1. The public health community committed to the control and elim-
ination of the NTDs is comprised predominantly of experts in
MDA. Because no NTD vaccines have yet been licensed there is
little or no familiarity with how such products might be incor-
porated into existing control programs.
2. Current public health efforts have focused on the concept of
control of soil-transmitted helminths rather than their elimina-
tion [28,29].  As outlined above a full consideration of helminth
transmission dynamics strongly suggests that MDA  is not suffi-
cient and that a vaccine will be required to eliminate hookworm
[29], although MDA  may  be sufficient to eliminate ascariasis and
trichuriasis [36].
3. Anthelminthic vaccines are still in early stages of clinical devel-
opment and are several years from being licensed.
These perceptions and attitudes represent barriers to the
widespread introduction and uptake of a newly licensed vaccine
for hookworm. To counter these barriers, a demand forecast for
the Human Hookworm Vaccine is now being conducted under
the auspices of the Bill & Melinda Gates Foundation, which will
assess the potential end-users of the vaccine and help the Sabin
ine 31
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accine Institute to develop a roadmap to eventual global use of
he vaccine in endemic regions.
.3. Commercial challenges
Similar to other major NTDs, hookworm infection occurs almost
xclusively among the poorest people living in low- and middle-
ncome countries [3].  Given that almost three-quarters of a billion
eople are currently infected with hookworm, the potential market
or a Human Hookworm Vaccine is vast. However, there is little if
ny commercial potential for such a product given that it would be
sed exclusively for the benefit of the world’s poorest. This lack of
nancial incentive contrasts with that of vaccines for HIV/AIDS or
uberculosis, which is endemic not only in developing countries but
lso in North America, Europe, and in some of the wealthier Asian
ations. To overcome this commercial barrier to development and
ventual use of a licensed hookworm vaccine, the Sabin Vaccine
nstitute is partnering with public sector vaccine manufacturers in
o-called innovative developing countries (IDCs) such as Brazil and
exico [38]. These organizations belong to the Developing Country
accine Manufacturers Network (DCVMN), which shares informa-
ion about best practices for manufacture, regulatory affairs, and
accine introduction [39].
For the Human Hookworm Vaccine, the Sabin Vaccine Insti-
ute is collaborating with the Oswaldo Cruz Foundation (FIOCRUZ)
or both clinical testing and industrial-scale manufacture [10]. To
mprove and scale up the processes for producing vaccine sup-
lies suitable for phase 2 and phase 3 clinical trials, and ultimately
or the industrial-scale manufacture of the vaccine, efforts have
een initiated to transfer the manufacturing technology for both
a-GST-1 and Na-APR-1 to FIOCRUZ, specifically with its vac-
ine production division known as Bio-Manguinhos. Ultimately,
IOCRUZ/Bio-Manguinhos will be a major global producer of the
uman Hookworm Vaccine, using an unrestricted license from
he Sabin Vaccine Institute. Preliminary estimates indicate that
 vaccine consisting of the two recombinant proteins (manu-
actured using the current methodologies) and adjuvanted with
lhydrogel® could be produced for less than $1 per dose. The
urrent regulatory strategy is to pursue registration in Brazil in
arallel with an application to the WHO  for prequalification of
he Brazilian-produced product, with distribution of vaccine to
ndemic countries worldwide through international procurement
gencies such as UNICEF and the Pan-American Health Organiza-
ion’s Revolving Fund.
. Future perspectives and concrete actions
Several concrete actions will be taken in the coming years to
dvance the development of the Human Hookworm Vaccine, which
f successful will ultimately lead to the vaccine’s licensure by 2020:
. Clinical development. Following phase 1 studies of each of the
recombinant antigens that will be included in the bivalent vac-
cine, they will be tested in combination for their ability to
prevent infection and intestinal blood loss. Such studies will be
conducted in children through a “proof-of-concept” phase 2b
study in Brazil in collaboration with the Rene Rachou Research
Center in Minas Gerais State (a member institute of the FIOCRUZ
network). In addition, the Sabin Vaccine Institute is developing
plans to provide an early assessment of efficacy by vaccinating
adult volunteers in the United States and challenging them with
N. americanus infectious larvae.
. Product development. In parallel, the Sabin Vaccine Institute
has initiated technology transfer to FIOCRUZ/Bio-Manguinhos
in order to produce vaccine supplies for phase 2 and phase 3S (2013) B227– B232 B231
testing. Goals of the manufacturing technology transfer include
improvement of protein expression yields for both Na-GST-1 and
Na-APR-1, and to manufacture a co-formulated product contain-
ing both antigens.
3. Regulatory strategy. The Sabin Vaccine Institute, in partnership
with FIOCRUZ, intends to first register the vaccine in Brazil while
in parallel applying to the WHO  for prequalification. However,
other options for regulatory approval are also under consider-
ation.
4. Demand forecasting.  This exercise will be extremely important
in providing justification for continued vaccine development and
will be essential to developing a roadmap to vaccine introduction
and uptake in Brazil and elsewhere in Latin America, as well as
in areas of high hookworm transmission in Africa and Asia. A
critical component of demand forecasting will require detailed
estimates of the costs for manufacturing and distributing the
vaccine.
4. Conclusions and lessons learned
Hookworm infection is one of the most common infections
of the world’s poorest people. The Human Hookworm Vaccine
is a key technology for the Global Vaccine Action Plan and the
Decade of Vaccines and an essential tool for achieving the MDGs,
especially those linked to maternal and child health. Product and
clinical development plans, as well as regulatory and global access
strategies, are in place for this vaccine, with the recognition that
development and vaccine introduction face important scientific,
programmatic, and commercial challenges as outlined above.
Among the lessons learned over the last decade of international
cooperation between the Sabin Vaccine Institute and FIOCRUZ are:
1. The importance of a strong evidence base to guide and justify
vaccine development. The scientists associated with the Sabin
Vaccine Institute have published more than 100 papers on hook-
worm vaccine development in the peer-reviewed biomedical
literature.
2. Frequent scientific exchanges and tight project and program
management are important to ensure success in technology
transfer from the Sabin Vaccine Institute product development
laboratories to cGMP manufacturers (especially in IDC  nations),
as are regular program reviews to assess the feasibility, integrity
and reproducibility of the manufacturing processes.
3. Developing a regulatory strategy and clinical development plans
in collaboration with regulatory agencies in the United States
and Brazil is critical to maintaining timelines and ultimately
licensing a vaccine.
4. The importance of advocacy to make the public health and sci-
entific community aware of the enormous threat of hookworm
infection to the health of at-risk children and pregnant women
living in low- and middle-income countries, together with a pro-
gram of education to inform the global public health community
about the limitations of MDA  as a single-dimension strategy for
the control and eventual elimination of hookworm infection.
In summary, the Human Hookworm Vaccine is an important
new technology and one that has the potential to significantly
reduce the prevalence and burden of iron-deficiency anemia in
low- and middle-income countries, to help achieve MDG  targets
related to maternal and child health, and to help reduce poverty in
the poorest regions of Africa, Asia, and Latin America. The Human
Hookworm Vaccine Initiative will also prove instructive for exist-
ing and new potential vaccine development initiatives targeting
neglected tropical diseases.
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